Katell Le Dû

3.0k total citations
20 papers, 124 citations indexed

About

Katell Le Dû is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Katell Le Dû has authored 20 papers receiving a total of 124 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Genetics and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Katell Le Dû's work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Thermal Regulation in Medicine (2 papers). Katell Le Dû is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Thermal Regulation in Medicine (2 papers). Katell Le Dû collaborates with scholars based in France, United States and Spain. Katell Le Dû's co-authors include Fabrice Denis, Hugues Bourgeois, Julien Dômont, L. Campion, Pauline du Rusquec, G. Ganem, Éric Voog, Philippe Solal‐Céligny, Olivier Dupuis and Jérôme Cornillon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Medical Internet Research.

In The Last Decade

Katell Le Dû

14 papers receiving 123 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katell Le Dû France	6	44	42	40	39	27	20	124
V. Filipazzi Italy	8	139 3.2×	14 0.3×	116 2.9×	19 0.5×	13 0.5×	19	195
Jamie E. Flerlage United States	8	43 1.0×	4 0.1×	15 0.4×	75 1.9×	12 0.4×	24	173
Laure Écotière France	6	22 0.5×	23 0.5×	8 0.2×	23 0.6×	55 2.0×	12	179
Herish Garresori Norway	9	149 3.4×	10 0.2×	56 1.4×	19 0.5×	5 0.2×	23	261
Christian Platini France	6	82 1.9×	15 0.4×	96 2.4×	3 0.1×	27 1.0×	13	149
Abhay K. Kattepur India	6	42 1.0×	4 0.1×	42 1.1×	11 0.3×	5 0.2×	29	89
Elie A Akl Malaysia	2	19 0.4×	54 1.3×	16 0.4×	3 0.1×	7 0.3×	2	129
Chai‐Ni Chang United States	6	25 0.6×	17 0.4×	397 9.9×	130 3.3×	130 4.8×	7	525
Mehmet Emin Güneş Türkiye	7	20 0.5×	8 0.2×	32 0.8×	6 0.2×	5 0.2×	23	109
Agnès Lequerrec France	4	53 1.2×	66 1.6×	9 0.2×	25 0.6×	20 0.7×	8	238

Countries citing papers authored by Katell Le Dû

Since Specialization

Citations

This map shows the geographic impact of Katell Le Dû's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katell Le Dû with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katell Le Dû more than expected).

Fields of papers citing papers by Katell Le Dû

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katell Le Dû. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katell Le Dû. The network helps show where Katell Le Dû may publish in the future.

Co-authorship network of co-authors of Katell Le Dû

This figure shows the co-authorship network connecting the top 25 collaborators of Katell Le Dû. A scholar is included among the top collaborators of Katell Le Dû based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katell Le Dû. Katell Le Dû is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dû, Katell Le, Adrien Chauchet, Olivier Fitoussi, et al.. (2025). Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma). JMIR Cancer. 11. e65960–e65960.

Franzoi, Maria Alice, Arlindo R. Ferreira, Antoine Lemaire, et al.. (2024). Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium. The Lancet Regional Health - Europe. 44. 101005–101005. 15 indexed citations

Dû, Katell Le, et al.. (2024). Anaemia in Hospitalized Cancer Patients: A Retrospective Study of Two Cohorts before and after the Guideline Update. Oncology Research and Treatment. 47(7-8). 331–339.

Dû, Katell Le, et al.. (2023). CTPS1 acts as a prognostic biomarker and therapeutic target in mantle cell lymphoma. Hematological Oncology. 41(S2). 253–254.

Dû, Katell Le, Anne-Lise Septans, Anna Schmitt, et al.. (2023). A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study. Journal of Medical Internet Research. 25. e38619–e38619. 6 indexed citations

Ferreira, Arlindo R., Antoine Lemaire, Joseph Rodriguez, et al.. (2023). Towards improvement of oncology care through digital technology: A snapshot of Resilience remote patient monitoring (RPM) system implementation across 19 hospitals in Europe.. Journal of Clinical Oncology. 41(16_suppl). 1518–1518.

Dû, Katell Le, et al.. (2022). Extranodal classical Hodgkin lymphoma involving the spinal cord: case report and review of the literature. CNS Oncology. 11(3). CNS88–CNS88.

Dû, Katell Le, Anne-Lise Septans, Frédéric Maloisel, et al.. (2021). A new option in pain prevention with bliss, a therapeutic virtual reality solution in bone marrow biopsy context: Results of a French open-label multicenter randomized phase II/III study (REVEH Trial).. Journal of Clinical Oncology. 39(15_suppl). 6573–6573.

Régny, Caroline, Lucie Obéric, Sandra Malak, et al.. (2019). PF482 CLINICAL EFFICACY OF THE RIBVD REGIMEN FOR REFRACTORY/RELAPSED (R/R) MANTLE CELL LYMPHOMA (MCL) PATIENTS: A RETROSPECTIVE STUDY OF THE LYSA GROUP. HemaSphere. 3(S1). 193–193. 1 indexed citations

10.

Ghesquières, Hervé, Olivier Casasnovas, Emmanuelle Nicolas‐Virelizier, et al.. (2019). Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA). Blood. 134(Supplement_1). 2832–2832. 4 indexed citations

11.

Pour, Luděk, Yvonne A. Efebera, Roman Hájek, et al.. (2019). PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR. HemaSphere. 3(S1). 257–258. 1 indexed citations

12.

Feugier, Pierre, Loïc Ysebaert, Alain Delmer, et al.. (2019). PF387 FRENCH IBRUTINIB OBSERVATIONAL STUDY (FIRE): REAL‐WORLD STUDY OF IBRUTINIB TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN FRANCE. HemaSphere. 3(S1). 145–146. 3 indexed citations

13.

Deau, Bénédicte, Sandy Amorim, Aurore Perrot, et al.. (2018). Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study. British Journal of Haematology. 181(3). 341–349. 7 indexed citations

14.

Denis, Fabrice, Éric Voog, Y. Pointreau, et al.. (2018). Prospective study of a web-mediated management of febrile neutropenia related to chemotherapy (Bioconnect). Supportive Care in Cancer. 27(6). 2189–2194. 4 indexed citations

15.

Pour, Luděk, Miquel Granell, Roman Hájek, et al.. (2018). The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data. Blood. 132(Supplement 1). 1967–1967. 3 indexed citations

16.

Voog, Éric, L. Campion, Pauline du Rusquec, et al.. (2017). Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer. Supportive Care in Cancer. 26(1). 81–89. 47 indexed citations

17.

Malak, Sandra, Pascale Cony‐Makhoul, Jean‐Christophe Ianotto, et al.. (2016). Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM). Blood. 128(22). 3123–3123. 3 indexed citations

18.

Lemaire, Pierre, et al.. (2014). Leucémie prolymphocytaire T : un piège diagnostique à connaître. Annales de Dermatologie et de Vénéréologie. 141(12). 777–781. 1 indexed citations

19.

Lamy, T., Gandhi Damaj, Emmanuel Gyan, et al.. (2014). R-CHOP with or without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group. Blood. 124(21). 393–393. 17 indexed citations

20.

Goede, Valentin, Anja Engelke, Kirsten Fischer, et al.. (2014). Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study. Blood. 124(21). 3327–3327. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact